fda shortage tirzepatide update reviews decision to put Lilly's on list FDA says shortage of GLP-1

These results represented a breakthrough in obesity pharmacotherapy and led to FDA approval of Zepbound

J Clin Endocrinol Metab (1986) 63:4928

Variability in body weight and the risk of cardiovascular complications in type 2 diabetes: results from the Swedish national diabetes register

When considering prescribing SSRIs for MDD management, consider assessing the patient for MDD first, taking a detailed health history, and discussing the risks versus benefits of starting SSRIs for this patient (1, 3)

Your provider will guide the transition, typically starting Zepbound at a lower dose even if youre on high-dose Wegovy, then gradually increasing